Patients with stage IIIB/IV or recurrent squamous NSCLC ( without prior systemic therapy for advanced disease ) received up to six @-week cycles of chemotherapy ( carboplatin , area under the curve @ mg/mLmin/paclitaxel , @ mg/m ) and were randomized @:@ to receive motesanib @ mg ( Arm A ) or placebo ( Arm B ) once daily .